RAC - Charts & Price Action, page-18203

So Race is seeking FDA approval for RC110?

If not, then while the 50 clinical trials may be nice historical data, Race really only has one drug - RC220.

If Race do plan on commercialising RC110, what's taking so long? 50 clinical trials shoul provide more than enough safety and efficacy data for regulatory approvals. Shouldn't RC110 be in the market now bringing in some revenue to fund the development of RC220?

I would argue that Imugene is more advanced than Race in terms of proximity to an FDA approval (let alone having a much broader pipeline, 2x FDA fast track designations).